公开(公告)号：EP2360252B8

公开(公告)日：2017-04-12

申请号：EP10186177.1

申请日：1997-10-30

申请人： University Of Iowa Research Foundation ,  THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

发明人： Krieg, Arthur ,  Klinman, Dennis ,  Weiner, George

IPC分类号： C12N15/11 ,  C07H21/00 ,  C07H21/04 ,  A61K31/7125 ,  A61P31/00 ,  A61P35/00

CPC分类号： A61K39/00 ,  A61K31/00 ,  A61K31/4706 ,  A61K31/7048 ,  A61K31/711 ,  A61K31/7125 ,  A61K39/39 ,  A61K2039/55561 ,  C07H21/00 ,  C12N15/117 ,  C12N2310/17 ,  C12N2310/315 ,  C12Q1/68 ,  Y02A50/412 ,  Y02A50/464 ,  Y02A50/466 ,  Y02A50/54

摘要： Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as synthetic adjuvant.

摘要翻译： 公开了含有调节免疫应答的非甲基化CpG二核苷酸的核酸序列，包括刺激免疫激活，细胞因子产生，NK溶解活性和B细胞增殖的Th1模式。 序列也可用作合成佐剂。

公开(公告)号：EP3146051A1

公开(公告)日：2017-03-29

申请号：EP15795373.8

申请日：2015-05-20

申请人： University of Iowa Research Foundation

发明人： DAVIDSON, Beverly, L. ,  MAS MONTEYS, Alejandro

IPC分类号： C12N15/113

摘要： The present invention is directed to RNA interference (RNAi) molecules targeted against a Huntington's disease nucleic acid sequence, and methods of using these RNAi molecules to treat Huntington's disease.

摘要翻译： 本发明涉及针对亨廷顿氏病核酸序列的RNA干扰（RNAi）分子，以及使用这些RNAi分子治疗亨廷顿氏病的方法。

公开(公告)号：EP2176283B1

公开(公告)日：2016-11-02

申请号：EP08781733.4

申请日：2008-07-11

申请人： University of Iowa Research Foundation ,  Davidson, Beverly L. ,  Chen, Yong Hong

发明人： DAVIDSON, Beverly, L. ,  CHEN, Yong Hong

IPC分类号： C07K14/025 ,  A61K48/00 ,  C12N15/00 ,  C12N15/34

CPC分类号： A61K38/162 ,  A61K48/00 ,  C07K5/08 ,  C07K5/10 ,  C07K7/06 ,  C07K14/005 ,  C07K2319/33 ,  C12N15/86 ,  C12N2750/14133 ,  C12N2750/14143 ,  C12N2750/14145 ,  C12N2810/40 ,  G01N33/5058

摘要： The present disclosure provides targeting peptides and vectors containing a sequence that encodes targeting peptides that deliver agents to the brain.

公开(公告)号：EP3024497A2

公开(公告)日：2016-06-01

申请号：EP14829704.7

申请日：2014-07-20

申请人： University of Iowa Research Foundation

发明人： DAVIDSON, Beverly L. ,  TECEDOR, Luis ,  CHEN, Yong Hong

IPC分类号： A61K48/00

CPC分类号： A61K48/0058 ,  A61K31/343 ,  A61K48/00 ,  A61K48/0075 ,  C12N2750/14143

摘要： The present disclosure provides methods of treating a disease or delivering a therapeutic agent to a mammal comprising administering to the mammal's cisterna magna and/or ventricle an rAAV particle containing a vector comprising a nucleic acid encoding a therapeutic protein inserted between a pair of AAV inverted terminal repeats in a manner such that cells with access to the cerebrospinal fluid (CSF) express the therapeutic agent and in certain embodiments secretes the therapeutic agent into the CSF for distribution to the brain.

摘要翻译： 本公开提供了治疗疾病或向哺乳动物递送治疗剂的方法，其包括对哺乳动物的大池和/或心室施用含有载体​​的rAAV颗粒，所述载体包含插入在一对AAV倒置末端之间的编码治疗性蛋白质的核酸 以使得具有进入脑脊液（CSF）的细胞表达治疗剂的方式重复，并且在某些实施方案中将治疗剂分泌到CSF中以分配给脑。

公开(公告)号：EP2996684A1

公开(公告)日：2016-03-23

申请号：EP14764138.5

申请日：2014-03-17

申请人： University of Iowa Research Foundation ,  BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

发明人： DAVIDSON, Beverly L. ,  STEIN, Colleen S. ,  SCHULTZ, Mark ,  TECEDOR, Luis ,  KIELIAN, Tammy L.

IPC分类号： A61K31/015 ,  A61K31/19 ,  A61K31/21

CPC分类号： A61K31/704 ,  A61K31/192 ,  A61K31/216 ,  A61K31/56

摘要： Certain embodiments of the present invention provide a method for treating or preventing juvenile neuronal ceroid lipofuscinosis (JNCL) in an animal comprising administering CBX, GRA, or GZA to the animal.

摘要翻译： 本发明的某些实施方案提供了用于治疗或预防动物中青少年神经元蜡样脂褐质沉着症（JNCL）的方法，其包括将CBX，GRA或GZA给予动物。

公开(公告)号：EP2986341A1

公开(公告)日：2016-02-24

申请号：EP14800597.8

申请日：2014-04-18

申请人： University of Iowa Research Foundation ,  Tarix Orphan, LLC.

发明人： SABHARWAL, Rasna ,  CHAPLEAU, Mark ,  FRANKLIN, Richard

IPC分类号： A61P21/00

CPC分类号： A61K38/085 ,  A61K31/4178 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention provides, among other things, methods of treating a muscular dystrophy including administering to a subject suffering from or susceptible to a muscular dystrophy an angiotensin (1-7) peptide. The present invention is, in part, based on the unexpected discovery that administration of an angiotensin (1-7) peptide in a muscular dystrophy animal model reduces fibrosis, restores locomotor activity and restores sympathovagal balance, which are characteristic symptoms in patients suffering from muscular dystrophy. Thus, the present invention provides a new and more effective therapy for muscular dystrophy. In some embodiments, an angiotensin (1-7) peptide includes the naturally occurring angiotensin (1-7) amino acid sequence of Asp1-Arg2-Val3-Tyr4-lle5 -His6-Pro7 (SEQID NO:1). In some embodiments, the angiotensin (1-7) peptide is a functional equivalent of SEQ ID NO:1. In some embodiments, the linear peptide has an amino acid sequence of Asp1-Arg2-Val3-Ser4-lle5-H'is6-Cys7 (SEQ ID NO:2). In some embodiments, the cyclic peptide is a 4,7-cyclized angiotensin (1-7).

摘要翻译： 本发明提供了治疗肌营养不良症的方法，包括给患有肌营养不良症或易患肌营养不良症的受试者服用血管紧张素（1-7）肽。 本发明部分基于意外的发现，即在肌营养不良动物模型中施用血管紧张素（1-7）肽减少纤维变性，恢复运动活性并恢复交感神经平衡，这是患有肌肉的患者的特征性症状 营养不良。 因此，本发明为肌营养不良提供了新的和更有效的疗法。 在一些实施方案中，血管紧张素（1-7）肽包括天然存在的Asp1-Arg2-Val3-Tyr4-Ile5-His6-Pro7（SEQ ID NO：1）的血管紧张素（1-7）氨基酸序列。 在一些实施方案中，血管紧张素（1-7）肽是SEQ ID NO：1的功能等同物。 在一些实施方案中，线性肽具有Asp1-Arg2-Val3-Ser4-Ile5-H'is6-Cys7（SEQ ID NO：2）的氨基酸序列。 在一些实施方案中，环肽是4,7-环化的血管紧张素（1-7）。

公开(公告)号：EP2302076B1

公开(公告)日：2014-11-12

申请号：EP10179501.1

申请日：2006-02-14

申请人： University of Iowa Research Foundation

发明人： Hageman, Gregory S. ,  Smith, Richard J.

IPC分类号： C12Q1/68

CPC分类号： C07K14/47 ,  A61K9/0048 ,  C07K14/435 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/172

摘要： The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD.

公开(公告)号：EP2768950A1

公开(公告)日：2014-08-27

申请号：EP12780376.5

申请日：2012-10-18

申请人： University of Iowa Research Foundation

发明人： SUBRAMANIAN, Venkiteswaran ,  LOUIE, Michael, Tai-Man ,  SUMMERS, Ryan

IPC分类号： C12N9/00 ,  C12N15/53 ,  C12N1/19 ,  C12N1/21 ,  C12P17/18 ,  C12Q1/26

CPC分类号： C12N9/0071 ,  C12N9/0073 ,  C12P17/182 ,  C12Q1/26 ,  C12Y114/13 ,  C12Y114/13128

摘要： The invention provides isolated nucleic acid encoding one or more gene products that allow for degradation of caffeine and related structures, and for preparation of intermediates in that catabolic pathway. Further provided are methods of using one or more of those gene products.

摘要翻译： 本发明提供编码一种或多种基因产物的分离的核酸，其允许咖啡因和相关结构的降解，以及在该分解代谢途径中制备中间体。 进一步提供使用一种或多种这些基因产物的方法。

公开(公告)号：EP2717876A1

公开(公告)日：2014-04-16

申请号：EP12796615.8

申请日：2012-06-06

申请人： University of Iowa Research Foundation ,  The United States of America as represented by The Secretary of State of The Department of Veterans Affairs

发明人： ADAMS, Christopher, M. ,  KUNKEL, Steven, D. ,  WELSH, Michael

IPC分类号： A61K31/473

CPC分类号： A61K31/58 ,  A61K31/215 ,  A61K31/352 ,  A61K31/353 ,  A61K31/36 ,  A61K31/382 ,  A61K31/404 ,  A61K31/407 ,  A61K31/4164 ,  A61K31/4166 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/436 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/4706 ,  A61K31/473 ,  A61K31/56 ,  A61K31/565 ,  C12Q1/6809 ,  C12Q2600/136 ,  G01N33/5023 ,  G01N2800/10 ,  G01N2800/52 ,  A61K2300/00

摘要： In one aspect, the invention relates to methods for treating muscle atrophy by providing to an animal in need thereof an effective amount of a compound. The compound can modulate the expression levels of multiple mRNA of a muscle atrophy signature. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. The disclosed compounds can treat muscle atrophy when administered in an effective amount to an animal, such as a mammal, fish or bird. For example, human. Also disclosed in a method of lowering blood glucose in an animal by administering ursolic acid or ursolic acid analogs, such as betulininc acid analogs, and narigenin analogs, such as naringenin, in an effective amount to an animal. Also disclosed in a method of lowering blood glucose in an animal by administering ungerine/hippeastrine analogs, such as hippeastrine, in an effective amount to an animal. The disclosed compounds can also promote muscle health, promote normal muscle function, and/or promote healthy aging muscles by providing to a subject in need thereof an effective amount of a disclosed compound.

公开(公告)号：EP2673286A1

公开(公告)日：2013-12-18

申请号：EP12745030.2

申请日：2012-02-13

申请人： University of Iowa Research Foundation

发明人： DAVIDSON, Beverly, L. ,  BOUDREAU, Ryan, L.

IPC分类号： C07H21/00 ,  C12N15/113

CPC分类号： C12N15/113 ,  A61K48/00 ,  C12N7/00 ,  C12N15/11 ,  C12N15/111 ,  C12N2310/141 ,  C12N2310/531 ,  C12N2320/30 ,  C12N2320/53 ,  C12N2330/51 ,  C12N2750/14143

摘要： The present invention is directed to RNA interference (RNAi) molecules targeted against a Huntington's disease nucleic acid sequence, and methods of using these RNAi molecules to treat Huntington's disease.

摘要翻译： 本发明涉及靶向亨廷顿病核酸序列的RNA干扰（RNAi）分子，以及使用这些RNAi分子来治疗亨廷顿舞蹈病的方法。